Evidence map›Paper›PMID 34800609›Full record

ArticleDiabetes research and clinical practice2021

Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial.

Mary R Rooney, Dan Wang, J William McEvoy, Stephen P Juraschek, John Chalmers, Mark Woodward, Elizabeth Selvin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes research and clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Mary R RooneyDepartment of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: mroone12@jhu.edu.
Dan WangDepartment of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
J William McEvoyDivision of Cardiology and National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland.
Stephen P JuraschekBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
John ChalmersThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Mark WoodwardThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; The George Institute for Global Health, Imperial College London, UK.
Elizabeth SelvinDepartment of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USThe George Institute for Global Health · AUBeth Israel Deaconess Medical Center · USOllscoil na Gaillimhe – University of Galway · IE

Funding

CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Elizabeth Selvin · 1985 to 2026
$17.5M
Alternative Biomarkers of Hyperglycemia in ADVANCER01DK108784 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2016 to 2019
$2.0M
Research and Mentoring in the Clinical Epidemiology of Cardiovascular Disease and Type 2 DiabetesK24HL152440 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2020 to 2024
$612k
NHLBI NIH HHS K24 HL152440NHLBI NIH HHS T32 HL007024NIDDK NIH HHS R01 DK108784
6 · The paper itself

Abstract

We found that 1,5-anhydroglucitol-a marker of glucose excursions-was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.

Indexed as

Diabetes Mellitus, Type 2Humans

Identifiers

PMID34800609
PMCPMC8688324
OpenAlexW3214892733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.